Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic

Pharmacotherapy
Michael P Veve, Jamie L Wagner

Abstract

The emergence and spread of antimicrobial resistance have led to a global public health emergency requiring development of new antimicrobial classes. Lefamulin (formally BC-3781) is a novel pleuromutilin antibiotic currently undergoing Food and Drug Administration review for community-acquired bacterial pneumonia (CABP) as intravenous (IV) and oral (PO) formulations. Although pleuromutilin antibiotics were first developed in the 1950s, lefamulin is the first to be used for systemic treatment of bacterial infections in humans. Lefamulin exhibits a unique mechanism of action through inhibition of protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of transfer RNA for peptide transfer. Lefamulin displays activity against gram-positive and atypical organisms associated with CABP (i.e., Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydophila pneumoniae), with an expanded gram-positive spectrum including Staphylococcus aureus (i.e., methicillin-resistant, vancomycin-intermediate, and heterogeneous strains) and vancomycin-resistant Enterococcus faecium. Lefamulin was also shown to retain activity against mu...Continue Reading

References

Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·M S NiedermanUNKNOWN American Thoracic Society
Jan 23, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kinan AttassiMarcus J Zervos
Jun 13, 2003·The Journal of Antimicrobial Chemotherapy·Robin Patel
Feb 6, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A MandellUNKNOWN American Thoracic Society
Dec 27, 2007·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Jm Conly, Bl Johnston
Mar 11, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·UNKNOWN Infectious Diseases Society of America
Dec 24, 2011·Annals of the New York Academy of Sciences·Rodger Novak
Jun 20, 2012·Emerging Infectious Diseases·Mina PastagiaStephen G Jenkins
Jul 21, 2012·Journal of Clinical Microbiology·James E RossRonald N Jones
Jan 16, 2015·American Journal of Respiratory and Critical Care Medicine·Brad SpellbergDavid N Gilbert
Oct 16, 2015·Proceedings of the National Academy of Sciences of the United States of America·Zohar EyalAda Yonath
Jul 16, 2016·MMWR. Surveillance Summaries : Morbidity and Mortality Weekly Report. Surveillance Summaries·Robert D KirkcaldyElizabeth Torrone
Jul 26, 2016·Frontiers in Microbiology·Sabine PereyreCécile Bébéar
Oct 1, 2016·Biochemical Pharmacology·Prabhavathi Fernandes, Evan Martens
Oct 16, 2016·Cold Spring Harbor Perspectives in Medicine·Susanne Paukner, Rosemarie Riedl
Apr 22, 2017·American Journal of Therapeutics·Regine CherazardMiriam A Smith
Aug 26, 2017·The Journal of Infectious Diseases·Catriona S BradshawKen B Waites
Oct 20, 2017·Emerging Infectious Diseases·Josephine B SlifirskiCatriona S Bradshaw

❮ Previous
Next ❯

Citations

Dec 5, 2018·Expert Review of Anti-infective Therapy·Caroline DillonJordan R Covvey
Oct 18, 2019·Expert Opinion on Pharmacotherapy·Matteo BassettiMaddalena Peghin
Jan 21, 2020·Expert Opinion on Pharmacotherapy·Vicenç FalcóBenito Almirante
Feb 7, 2020·Journal of Asian Natural Products Research·Hui-Xian LiuFei-Qun Xue
Apr 3, 2020·Expert Opinion on Drug Safety·Carla BastidaAntoni Torres
Mar 30, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard R Watkins, Thomas M File
Nov 19, 2019·Frontiers in Pharmacology·Yang LiuBirong Dong
Jul 25, 2020·Medicine·Hung-Jen TangChih-Cheng Lai
Sep 29, 2020·The Journal of Antibiotics·Timm Anke
Mar 11, 2020·The Journal of Antibiotics·Mark S Butler, David L Paterson
Jan 16, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Martti Vaara
Oct 9, 2019·Expert Opinion on Emerging Drugs·Matteo BassettiMark Wilcox
Apr 23, 2019·Expert Review of Anti-infective Therapy·Georgios L VoulgarisMatthew E Falagas
Aug 25, 2020·Current Infectious Disease Reports·Nicholas J Mercuro, Michael P Veve
Sep 1, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Raphaël E DuvalBéatrice Demoré
Nov 2, 2019·Lung India : Official Organ of Indian Chest Society·Sandeep NayarRishi Jain
Feb 3, 2021·Infectious Diseases and Therapy·Nathaniel EraikhuemenDovena Lazaridis
Jan 12, 2021·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Alessandro Russo
Jan 22, 2021·Bioorganic & Medicinal Chemistry Letters·Qidi Kong, Yushe Yang
Mar 19, 2021·Journal of Enzyme Inhibition and Medicinal Chemistry·Yuanyuan ZhangZhouyu Wang
Mar 31, 2021·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
Oct 17, 2020·Planta medica·Violette HamersAurélie Urbain
Jan 27, 2019·Journal of the American Chemical Society·Benjamin J Huffman, Ryan A Shenvi
Apr 27, 2019·Journal of Medicinal Chemistry·Audrey E Yñigez-Gutierrez, Brian O Bachmann
Aug 28, 2021·Antibiotics·Firzan NainuJesus Simal-Gandara
Oct 5, 2021·Infection·Jaffar A Al-TawfiqPatricia Schlagenhauf
Feb 1, 2022·Expert Opinion on Pharmacotherapy·Susanna EspositoNicola Principi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.